SEC Form 6-K filed by Genmab A/S

$GMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GMAB alert in real time by email
6-K 1 tmb-20250123x6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JANUARY 2025


COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

nthony

GENMAB A/S

BY:

/s/ Anthony Pagano

Name: Anthony Pagano

Title: Executive Vice President & Chief Financial Officer

DATE: JANUARY 23, 2025


EXHIBIT INDEX

O

Exhibit

Description of Exhibit

99.1

Company Announcement Dated January 23, 2025: Grant of Restricted Stock Units and Warrants to Employees in Genmab


Get the next $GMAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GMAB

DatePrice TargetRatingAnalyst
2/13/2025$27.00Market Perform → Outperform
Leerink Partners
10/8/2024Buy
Redburn Atlantic
9/4/2024$31.00Equal-Weight
Morgan Stanley
8/20/2024Overweight → Neutral
JP Morgan
7/15/2024Sector Perform → Outperform
RBC Capital Mkts
2/23/2024$46.00 → $48.00Market Perform → Outperform
BMO Capital Markets
1/22/2024Neutral → Sell
Citigroup
12/6/2023Neutral → Buy
UBS
More analyst ratings

$GMAB
Press Releases

Fastest customizable press release news feed in the world

See more
  • EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

    Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who had received two or more lines of systemic therapy EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in Japan to treat both R/R FL and R/R large B-cell lymphomas, after two or more prior lines of therapy EPKINLY is the only bispecific antibody approved with a dual indication for the treatment of certain B-cell malignancies in the United States, European Union and Japan Genmab A/S (NASDAQ:GMAB) announced today that the Japan Ministry of Health,

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Genmab Publishes 2024 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

    Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both th

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GMAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GMAB
SEC Filings

See more

$GMAB
Leadership Updates

Live Leadership Updates

See more
  • Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

    Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GMAB
Financials

Live finance-specific insights

See more
  • Genmab Publishes 2024 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

    Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumors Genmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

    Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumorsGenmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark and SEATTLE, Washington; April 3, 2024 – Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have

    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GMAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more